Ireland· IE-PA-EU/1/23/1728/001
Tibsovo 250 mg Film-coated tablet
A ivosidenib product containing ivosidenib, registered in Ireland by Les Laboratoires Servier. The same ATC class is registered in 11 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Ivosidenib is registered in 11 of 19 countries.
Countries holding a registration under ATC L01XM02 (ivosidenib), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 8 of them publish a price we can compare per daily dose
Ivosidenib · ATC L01XM02
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- Ivosidenib
- Manufacturer
- Les Laboratoires Servier
- Country
- Ireland (IE)
- ATC code
- L01XM02
- ATC class
- Ivosidenib
- Defined daily dose
- 0.5 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/23/1728/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
516 interactions on record for ivosidenib.
Graded by severity as the source publishes them — 278 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ivosidenib · interactions on record
516 records
- 278 severe
- 223 moderate
- 15 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ivosidenib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumTibsovo 250 mgLes Laboratoires Servier
- SwitzerlandTibsovo 250 mg, comprimés pelliculésServier (Suisse) SA
- CzechiaTIBSOVOLes Laboratoires Servier, Suresnes cedex
- SpainTIBSOVO 250 MG COMPRIMIDOS RECUBIERTOS CON PELICULALes Laboratoires Servier
- FinlandTibsovoLes Laboratoires Servier
- FranceTIBSOVO 250 mg, comprimé pelliculéLES LABORATOIRES SERVIER
- IcelandTibsovoLes Laboratoires Servier*
- NetherlandsTibsovo 250 mg, filmomhulde tablettenLes Laboratoires Servier
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tibsovo
- Liechtenstein · Tibsovo
- Norway · Tibsovo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6ecd6085-003d-461c-8787-8ad130c0810e GET /v1/drugs/6ecd6085-003d-461c-8787-8ad130c0810e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"L01XM02"
],
"strength": null,
"pa_number": "EU/1/23/1728/001",
"substances": [
"Ivosidenib"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "04/05/2023",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about ivosidenib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.